Serving hundreds of leading biopharmaceutical companies globally:

Generated: November 20, 2018

DrugPatentWatch Database Preview

TAKEDA Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA, and what generic alternatives to TAKEDA drugs are available?

TAKEDA has twenty-one approved drugs.

There are eighty-six US patents protecting TAKEDA drugs.

Summary for TAKEDA

US Patents:	86
Tradenames:	22
Ingredients:	16
NDAs:	21
Patent Litigation for TAKEDA:	See patent lawsuits for TAKEDA
PTAB Cases with TAKEDA as patent owner:	See PTAB cases with TAKEDA as patent owner

Drugs and US Patents for TAKEDA

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-001	Jan 25, 2013		RX	Yes	No	8,637,079	➤ Sign Up	Y			➤ Sign Up
Takeda Pharms Usa	NESINA	alogliptin benzoate	TABLET;ORAL	022271-003	Jan 25, 2013		RX	Yes	Yes	8,288,539	➤ Sign Up		Y		➤ Sign Up
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009		RX	Yes	No	8,105,626*PED	➤ Sign Up			Y	➤ Sign Up
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-002	Jan 25, 2013		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for TAKEDA

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-002	Aug 30, 2002	5,013,743*PED	➤ Sign Up
Takeda Pharms Usa	NESINA	alogliptin benzoate	TABLET;ORAL	022271-002	Jan 25, 2013	6,329,404	➤ Sign Up
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-001	Aug 30, 2002	5,013,743*PED	➤ Sign Up
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009	6,172,090	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for TAKEDA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	15 mg/500 mg and 15 mg/850 mg	➤ Subscribe	2008-03-06
➤ Subscribe	Tablets	30 mg/2 mg and 30 mg/4 mg	➤ Subscribe	2009-12-22
➤ Subscribe	Tablets	6.25 mg, 12.5 mg and 25 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	5 mg, 10 mg, 15 mgand 20 mg	➤ Subscribe	2017-10-02
➤ Subscribe	Delayed-release Pellets/Capsul	15 mg and 30 mg	➤ Subscribe	2005-12-05
➤ Subscribe	Capsule	60 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg	➤ Subscribe	2011-09-23
➤ Subscribe	Tablets	0.6 mg	➤ Subscribe	2011-12-23
➤ Subscribe	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	8 mg	➤ Subscribe	2009-07-22
➤ Subscribe	Tablets	40 mg and 80 mg	➤ Subscribe	2013-02-13
➤ Subscribe	Delayed-release Orally Disinte	15 mg and 30 mg	➤ Subscribe	2006-12-27
➤ Subscribe	Delayed-release Capsule	30 mg	➤ Subscribe	2010-11-30

International Patents for TAKEDA Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Cyprus	1109028	➤ Sign Up
Peru	08822009	➤ Sign Up
Hungary	230189	➤ Sign Up
Tunisia	2009000317	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for TAKEDA Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2010005,C1020454	Lithuania	➤ Sign Up	PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004, 0080421
/2010	Austria	➤ Sign Up	PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2014 00066	Denmark	➤ Sign Up	PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919
2007 00001	Denmark	➤ Sign Up
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant

Dow

Healthtrust

Daiichi Sankyo

Mallinckrodt

McKesson

Baxter

Moodys

Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.